ADAPY:OTCMKTS
Adaptimmune Therapeutics PLC - ADR
US$ 0.038
0.00%
(0.00) Siku 1
1 Okt, 16:00:00 GMT -4 · USD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya ADAPY...
Fungua
US$ 0.04
Juu
US$ 0.04
Chini
US$ 0.03
Mtaji wa soko
9.57M
Wastani wa kiasi cha mauzo
elfu 205.25
Kiasi cha mauzo ya hisa
elfu 229.54
Juu kwa wiki 52
US$ 0.28
Chini kwa wiki 52
US$ 0.00
Beta
0.83
Hisa za wawekezaji
265.05M
Idadi ya wafanyakazi
272
Fungua
US$ 0.04
Juu
US$ 0.04
Chini
US$ 0.03
Mtaji wa soko
9.57M
Wastani wa kiasi cha mauzo
elfu 205.25
Kiasi cha mauzo ya hisa
elfu 229.54
Juu kwa wiki 52
US$ 0.28
Chini kwa wiki 52
US$ 0.00
Beta
0.83
Hisa za wawekezaji
265.05M
Idadi ya wafanyakazi
272
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Investor's Business Daily
·
dakika 8 zilizopita
Twilio To Join S&P 500 Index
CryptoRank
·
dakika 42 zilizopita
OpenWorld Begins Nasdaq Trading As VerifyMe Deal Creates Public Tokenization Company
Fox Business
·
saa 12 zilizopita
October could be a huge month for the stock market. Here's why.
Seeking Alpha
·
saa 2 zilizopita
Inside The September 2026 S&P 500 Momentum Index Reconstitution
Wasifu
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma.
In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
Kuhusu Adaptimmune Therapeutics PLC - ADR
Afisa Mkuu Mtendaji (CEO)Adrian Rawcliffe
Wafanyakazi272
Lilianzishwa2008
Makao makuu-
Sekta-
Tovutiadaptimmune.com